Bibliography
- LORENZ H-M: TNF inhibitors in the treatment of arthritis. Curr. Opin. Invest. Drugs (2000) 1:188–193.
- Novel N-hydroxamic acid hydrazide inhibitors of INF-a synthesis. Exp. Opin. Ther. Patents (2000) 10:1617–1621.
- CERRETTI DP: Characterization of the tumour necrosisfactor alpha-converting enzyme, TACE/ADAM17 . Biochem. Soc. Trans. (1999) 2:219–223.
- KILLAR L, WHITE J, BLACK R, PESCHON J: Adamalysins.Afamily of metzincins including TNF-alpha converting enzyme (TACE). Ann. NY Acad. Sci. (1999) 878: 442–452
- •One of a number of useful review articles on TACE.
- NORMAN P: New drug targets in inflammation andimmunomodulation. Drug News Perspect. (1998) 11:442–447.
- NORMAN P: Medicinal chemistry in Eastern England,tenth symposium. IDrugs (1999) 2:659–663.
- MONTANA JC, BAXTER AD: The design of selectivenon-substrate-based matrix metalloproteinase inhibi-tors. Curr. Opin. Drug Discover)/ Dev. (2000) 3:353–361.
- •Useful review that summarises the profile of activity of many leading MMP inhibitors.
- DAVIS JM, VENKATESAN A, BAKER JL et al: Novel4-substituted phenylsulfanyl alkyl and aryl hydrox-amic acid TACEand MMP inhibitors. ACS 219th National Meeting. (2000) MEDI 281.
- KINCAID SL, ZI BI Y, LEVIN JI et al.: Parallel synthesis andbiological activity of anthranilic hydroxamic acid MMP inhibitors. ACS 220th National Meeting. (2000) MEDI 55.
- SKOTNICKI J: The discovery of a novel class of potentTACE inhibitors: potential treatment of rheumatoid arthritis. Inflammation Research Association 10th National Conference (2000).
- LEVIN JI, ALBRIGHT JD, AYRAL-KALOUSTIAN S et al.:Design, synthesis and biological evaluation of a new class of TNFoc converting enzyme inhibitors for the treatment of rheumatoid arthritis. Inflammation Research Association 10th National Conference (2000) S94:2–65.